Lung Caner study 1:

Study name:

A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT04736173)

Eligibility:

Participants with locally advanced disease, treatment naïve and must not be eligible to receive other potentially curative therapies.

Treatment 1:

Zimberelimab (AB122) and Domvanalimab

Treatment 2:

Pembrolizumab

Lung Caner study 2: (Completed recruitment)

Study name:

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Eligibility:

Patients with unresectable, locally advanced or metastatic NSCLC with KRAS G12C mutation and disease progression on or after treatment with a platinum-based regimen and an immune checkpoint inhibitor.

Treatment 1:

MRTX849

Treatment 2:

Docetaxel